ArticleScience advances2025
Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus M
Abstract read
In one paragraph
Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Repurposing drug screen for the identification of helicase inhibitors from viruses of pandemic concern.SLAS discovery : advancing life sciences R & D · 2026Article
- Addressing the zoonotic threat of merbecoviruses.Nature microbiology · 2026Review
- Inhibiting the interaction between the mitochondrial receptor Tom70 and SARS CoV 2 Orf9b with small molecules.bioRxiv : the preprint server for biology · 2026Article
- Coupling high-throughput protease enzymology with viral replication reveals biochemical constraints of viral fitness.bioRxiv : the preprint server for biology · 2026Article
- Discovery of Coronavirus Main Protease Inhibitors with Enhanced Brain Exposure and Potent Oral Efficacy in SARS-CoV-2 and MERS Infection Models.Journal of medicinal chemistry · 2026Article
- SARS-CoV-2 Mpro inhibitor ensitrelvir: asymmetrical cross-resistance with nirmatrelvir and emerging resistance hotspots.Emerging microbes & infections · 2025Article
- Identifying protease-activated targets and exploring therapeutic applications.Expert opinion on therapeutic targets · 2025Review
- Review
- Open-science discovery of DNDI-6510, a compound that addresses genotoxic and metabolic liabilities of the COVID Moonshot SARS-CoV-2 Mpro lead inhibitor.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors.
Tyler C DetomasiDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0003-4390-108X
Gilles DegotteDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0001-6318-4626
Sijie HuangDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0001-5653-0260
Rahul K SuryawanshiGladstone Institute of Virology, Gladstone Institutes, San Francisco, CA, USA.ORCID 0000-0001-8374-669X
Amy DialloDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.
Luca LizzadroDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.
Francisco J Zapatero-BelinchónGladstone Institute of Virology, Gladstone Institutes, San Francisco, CA, USA.
Taha Y TahaGladstone Institute of Virology, Gladstone Institutes, San Francisco, CA, USA.ORCID 0000-0002-7344-7490
Jiapeng LiDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0003-4321-1150
Alicia L RichardsGladstone Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, CA, USA.
Eric R HantzDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-2588-7619
Zain AlamDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.
Mauricio MontanoGladstone Institute of Virology, Gladstone Institutes, San Francisco, CA, USA.ORCID 0000-0002-0353-0037
Maria McCavitt-MalvidoGladstone Institute of Virology, Gladstone Institutes, San Francisco, CA, USA.
Rajesh GumpenaDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.
James R PartridgeDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-5652-4351
Galen J CorreyDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0001-5155-7325
Yusuke MatsuiGladstone Institute of Virology, Gladstone Institutes, San Francisco, CA, USA.
Annemarie F CharvatDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.ORCID 0009-0002-1164-4816
Isabella S GlennDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.ORCID 0009-0002-6443-1873
Julia RosecransGladstone Institute of Virology, Gladstone Institutes, San Francisco, CA, USA.ORCID 0009-0000-3111-5933
Jezrael L RevaldeDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.
Dashiell AndersonDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.
Judd F HultquistDivision of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.ORCID 0000-0001-6424-4280
Michelle R ArkinDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-9366-6770
R Jeffrey NeitzDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-2247-9345
Danielle L SwaneyDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0001-6119-6084
Nevan J KroganGladstone Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, CA, USA.ORCID 0000-0003-4902-337X
Brian K ShoichetDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-6098-7367
Kliment A VerbaDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-2238-8590
Melanie OttGladstone Institute of Virology, Gladstone Institutes, San Francisco, CA, USA.ORCID 0000-0002-5697-1274
Adam R RensloDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-1240-2846
Charles S CraikDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0001-7704-9185
Funding
Targeting Viroporins and Coronavirus M ProteinU19AI171110 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI James Solomon Fraser · 2022 to 2026
$103.4MViral and Host Dynamics during Pediatric COVID-19 and Respiratory Virus Co-InfectionR01AI177498 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Bria M Coates, Judd F Hultquist · 2024 to 2026
$2.4MNIAID NIH HHS R01 AI177498NIAID NIH HHS U19 AI171110
Abstract
The main protease (M
Indexed as
Antiviral AgentsCoronavirus 3C ProteasesCOVID-19 Drug TreatmentProtease InhibitorsSARS-CoV-2AnimalsCOVID-19CytidineDrug DiscoveryHumansHydroxylaminesLactamsLeucineMiceMolecular Docking SimulationNitrilesAntiviral AgentsCoronavirus 3C ProteasesCytidineHydroxylaminesLactamsLeucinemolnupiravirnirmatrelvirNitrilesProlineProtease Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.